Outcomes After Platinum- and Non–Platinum-Based First-Line Chemotherapy Among Patients With HER2− Metastatic Breast Cancer With and Without Pathogenic Germline BRCA1/2 Mutations
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
British Journal of Cancer
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Outcomes of patients with HER2-negative metastatic breast cancer after platinum- and non-platinum-based first-line chemotherapy among patients with and without pathogenic germline BRCA1/2 mutations
Br. J. Cancer 2022 Oct 07;[EPub Ahead of Print], W Jacot, A Lusque, C Vicier, A Mailliez, T de La Motte Rouge, L Cabel, C Levy, A Patsouris, I Desmoulins, L Uwer, JC Thery, M Robain, O Caron, O Tredan, T Filleron, JS Frenel, S DelalogeFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.